98 related articles for article (PubMed ID: 33399314)
1. Triplet combination of BRAF, MEK and PD-1/PD-L1 blockade in melanoma: the more the better?
Trojaniello C; Vitale MG; Ascierto PA
Curr Opin Oncol; 2021 Mar; 33(2):133-138. PubMed ID: 33399314
[TBL] [Abstract][Full Text] [Related]
2. COLUMBUS-AD: phase III study of adjuvant encorafenib + binimetinib in resected stage IIB/IIC BRAF V600-mutated melanoma.
van Akkooi AC; Hauschild A; Long GV; Mandala M; Kicinski M; Govaerts AS; Klauck I; Ouali M; Lorigan PC; Eggermont AM
Future Oncol; 2023 Sep; 19(30):2017-2027. PubMed ID: 37665297
[TBL] [Abstract][Full Text] [Related]
3. Anti-PD-(L)1 plus BRAF/MEK inhibitors (triplet therapy) after failure of immune checkpoint inhibition and targeted therapy in patients with advanced melanoma.
Albrecht LJ; Dimitriou F; Grover P; Hassel JC; Erdmann M; Forschner A; Johnson DB; Váraljai R; Lodde G; Placke JM; Krefting F; Zaremba A; Ugurel S; Roesch A; Schulz C; Berking C; Pöttgen C; Menzies AM; Long GV; Dummer R; Livingstone E; Schadendorf D; Zimmer L
Eur J Cancer; 2024 May; 202():113976. PubMed ID: 38484692
[TBL] [Abstract][Full Text] [Related]
4. First-line therapy-stratified survival in BRAF-mutant melanoma: a retrospective multicenter analysis.
Schilling B; Martens A; Geukes Foppen MH; Gebhardt C; Hassel JC; Rozeman EA; Gesierich A; Gutzmer R; Kähler KC; Livingstone E; Diamantopoulos PT; Gogas H; Madonna G; Ascierto PA; Goldinger SM; Mangana J; Garbe C; Schadendorf D; Blank C; Weide B
Cancer Immunol Immunother; 2019 May; 68(5):765-772. PubMed ID: 30806748
[TBL] [Abstract][Full Text] [Related]
5. STARBOARD: encorafenib + binimetinib + pembrolizumab for first-line metastatic/unresectable
Schadendorf D; Dummer R; Robert C; Ribas A; Sullivan RJ; Panella T; McKean M; Santos ES; Brill K; Polli A; Pietro AD; Ascierto PA
Future Oncol; 2022 Jun; 18(17):2041-2051. PubMed ID: 35272485
[TBL] [Abstract][Full Text] [Related]
6. Factors associated with ocular adverse event after immune checkpoint inhibitor treatment.
Kim YJ; Lee JS; Lee J; Lee SC; Kim TI; Byeon SH; Lee CS
Cancer Immunol Immunother; 2020 Dec; 69(12):2441-2452. PubMed ID: 32556494
[TBL] [Abstract][Full Text] [Related]
7. Current Insights into Combination Therapies with MAPK Inhibitors and Immune Checkpoint Blockade.
Shin MH; Kim J; Lim SA; Kim J; Lee KM
Int J Mol Sci; 2020 Apr; 21(7):. PubMed ID: 32260561
[TBL] [Abstract][Full Text] [Related]
8. The ERK inhibitor LY3214996 augments anti-PD-1 immunotherapy in preclinical mouse models of BRAFV600E melanoma brain metastasis.
de Sauvage MA; Torrini C; Nieblas-Bedolla E; Summers EJ; Sullivan E; Zhang BS; Batchelor E; Marion B; Yamazawa E; Markson SC; Wakimoto H; Nayyar N; Brastianos PK
Neuro Oncol; 2024 May; 26(5):889-901. PubMed ID: 38134951
[TBL] [Abstract][Full Text] [Related]
9. Sustained release hydrogel for durable locoregional chemoimmunotherapy for BRAF-mutated melanoma.
Kim J; Archer PA; Manspeaker MP; Avecilla ARC; Pollack BP; Thomas SN
J Control Release; 2023 May; 357():655-668. PubMed ID: 37080489
[TBL] [Abstract][Full Text] [Related]
10. The immune response-related genomic alterations in patients with malignant melanoma.
Li L; Xiang T; Li X
Medicine (Baltimore); 2024 Apr; 103(17):e37966. PubMed ID: 38669390
[TBL] [Abstract][Full Text] [Related]
11. Regorafenib in patients with pretreated advanced melanoma: a single-center case series.
Vander Mijnsbrugge AS; Cerckel J; Dirven I; Tijtgat J; Vounckx M; Claes N; Neyns B
Melanoma Res; 2024 May; ():. PubMed ID: 38801446
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms of Acquired BRAF Inhibitor Resistance in Melanoma: A Systematic Review.
Proietti I; Skroza N; Bernardini N; Tolino E; Balduzzi V; Marchesiello A; Michelini S; Volpe S; Mambrin A; Mangino G; Romeo G; Maddalena P; Rees C; Potenza C
Cancers (Basel); 2020 Sep; 12(10):. PubMed ID: 33003483
[TBL] [Abstract][Full Text] [Related]
13. Rapid diurnal variation of serous retinal detachment during BRAF and MEK inhibitor treatment: A case series.
Bravetti GE; Muggler K; Ben Aissa A; Thumann G; Malclès A
Acta Ophthalmol; 2024 Jun; 102(4):e651-e656. PubMed ID: 38235944
[No Abstract] [Full Text] [Related]
14. BRAF
Finke C; Mohr P
Adv Ther; 2024 May; ():. PubMed ID: 38806993
[TBL] [Abstract][Full Text] [Related]
15. Metastatic Melanoma Treatment in Special Populations.
Miceli M; Boatwright C; Mehnert JM
Cancer J; 2024 Mar-Apr 01; 30(2):71-78. PubMed ID: 38527259
[TBL] [Abstract][Full Text] [Related]
16. [Advanced melanoma with low-burden and low-risk disease: a clinical case.].
Bersanelli M
Recenti Prog Med; 2024 May; 115(5):7e-12e. PubMed ID: 38708540
[TBL] [Abstract][Full Text] [Related]
17. [Side effects of dermato-oncologic therapies].
Hassel JC; Zimmer L
Dermatologie (Heidelb); 2024 Jun; 75(6):466-475. PubMed ID: 38802653
[TBL] [Abstract][Full Text] [Related]
18. A case of class 3
Wang C; Sandhu J; Fakih M
J Gastrointest Oncol; 2019 Dec; 10(6):1140-1143. PubMed ID: 31949931
[TBL] [Abstract][Full Text] [Related]
19. Phase i trials in melanoma: A framework to translate preclinical findings to the clinic.
Kim E; Rebecca VW; Smalley KS; Anderson AR
Eur J Cancer; 2016 Nov; 67():213-222. PubMed ID: 27689717
[TBL] [Abstract][Full Text] [Related]
20. Identification of dynamic microbiota signatures in patients with melanoma receiving ICIs: opportunities and challenges.
Maleki Vareki S; Davar D
Nat Rev Clin Oncol; 2024 Jun; 21(6):405-406. PubMed ID: 38509333
[No Abstract] [Full Text] [Related]
[Next] [New Search]
